Sydney, 12 March 2018: Noxopharm (ASX:NOX) is pleased to release its latest corporate presentation following the release of an interim report on clinical data from the CEP-1 clinical study.
The Company currently is pursuing 3 distinct uses of its experimental drug, NOX66:
- enhancement of external beam radiotherapy (DARRT program) in late-stage prostate cancer
- enhancement of intravenous brachytherapy radiotherapy (LUPIN program) in late-stage prostate cancer
- combination with low-dose carboplatin chemotherapy (CEP program) in common solid cancers.
For further information please download PDF attached:
Download this document
